research Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
Search
forLearn
0 / 0 results — no results
Research
5 / 19 resultsresearch Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research PRMT5 Inhibition Has a Potent Anti-Tumor Activity Against Adenoid Cystic Carcinoma of Salivary Glands
PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines
Early intervention and tailored management can reduce skin side effects from cancer treatments.
Community Join
0 / 0 results — no results